Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy
NCT02216916
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
49
Enrollment
OTHER
Sponsor class
Conditions
HNSCC
Interventions
DRUG:
HM781-36B
Sponsor
Yonsei University